Unum Therapeutics to Present Preclinical Data on Applications of ACTR Proprietary Technology Platform in Solid Tumors at the San Antonio Breast Cancer Symposium
November 09, 2018 14:31 ET
|
Unum Therapeutics Inc.
Initiating Phase 1 ATTCK-34-01 Trial in HER2+ Advanced Cancers by Year-End CAMBRIDGE, Mass., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage...
Unum Therapeutics to Present Preclinical Data on a New, Emerging Platform Technology for Solid Tumors at the SITC Annual Meeting
November 06, 2018 08:01 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), today announced that the Company will present preclinical data on a new proprietary technology platform...
Unum Therapeutics to Host Third Quarter 2018 Financial Results Conference Call and Webcast on November 12, 2018 at 4:30 P.M. ET
November 05, 2018 07:00 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies based on...
Unum Therapeutics to Present Preliminary Results from Ongoing Phase 1 Studies ATTCK-20-03 and ATTCK-17-01 at the 2018 ASH Annual Meeting
November 01, 2018 09:01 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies based on...
Unum Therapeutics Announces Abstract Accepted for Presentation at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
September 17, 2018 07:00 ET
|
Unum Therapeutics Inc.
-Complete Responses Observed in Three of Six Patients with relapsed or refractory CD20-positive B cell non-Hodgkin Lymphoma at Dose Level 1 of the ATTCK-20-03 Phase I Study - - No SAEs of Cytokine...
Unum Therapeutics to Present at Morgan Stanley 16th Annual Global Healthcare Conference
September 07, 2018 07:00 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies based on...
Unum Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update
August 13, 2018 16:05 ET
|
Unum Therapeutics Inc.
– IND for First Solid Tumor Program, ACTR T cells in Combination with Trastuzumab in Patients with HER2+ Advanced Cancers Now Active; Expect to Initiate Phase I Trial by End of 2018 – CAMBRIDGE,...
Unum Therapeutics Announces Active Investigational New Drug (IND) Application for Antibody-Coupled T Cell Receptor (ACTR) platform in Combination with Trastuzumab in Patients with HER2+ Advanced Cancers
August 13, 2018 16:05 ET
|
Unum Therapeutics Inc.
– First Solid Tumor Product Candidate Based on Unum’s universal ACTR Technology – – Phase 1 Study Expected to Initiate by the End of 2018 – CAMBRIDGE, Mass., Aug. 13, 2018 (GLOBE NEWSWIRE) --...
Unum Therapeutics to Present at Two Upcoming Investor Conferences
August 08, 2018 07:00 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ:UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies based on...
Unum Therapeutics to Host Second Quarter 2018 Financial Results Conference Call and Webcast on August 13, 2018 at 5:00 P.M. ET
August 06, 2018 07:00 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq:UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies based on...